CTChihiro Tsukahara

Chihiro Tsukahara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chihiro Tsukahara has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Three-Year Outcomes of Microhook ab Interno Trabeculotomy Combined with Phacoemulsification in Japanese Patients with Cataract and Open-Angle Glaucoma

    by Kana Sase, Yasushi Kitaoka, Chihiro Tsukahara, Yasuhiro Toyoda, Ayaka Tsukamoto, Naoto Tokuda

    Background and Objectives: This study aimed to report the efficacy of microhook ab interno trabeculotomy with phacoemulsification three years after the operation. Materials and Methods: This retrospective observational study over 3 years included 16 glaucoma patients (27 eyes) who underwent microhook ab interno trabeculotomy with phacoemulsification at St. Marianna University Hospital from April 2020 to March 2021. Preoperative and postoperative best-corrected visual acuity (BCVA), intraocular pressure (IOP), antiglaucoma medication scores, and mean deviation (MD) slope were analyzed. Results: The preoperative mean IOP was 16.2 ± 4.4 mmHg, and this IOP decreased significantly to 12.6 ± 1.8, 13.0 ± 2.1, 12.0 ± 1.8, 12.4 ± 2.0, 12.6 ± 1.9 and 12.3 ± 1.3 mmHg at 6, 12, 18, 24, 30 and 36 months after the operation, respectively. The preoperative mean BCVA (LogMAR) was 0.1 ± 0.2 and this was improved significantly to 0.012 ± 0.20, 0.0078 ± 0.20, 0.0013 ± 0.16, −0.001 ± 0.14, 0.007 ± 0.17, and 0.010 ± 0.20 at 6, 12, 18, 24, 30 and 36 months after the operation. The preoperative antiglaucoma medication score was 3.11 ± 1.26, and this score decreased significantly to 0.22 ± 0.62, 0.44 ± 0.79, 0.48 ± 0.79, 0.63 ± 0.87, 0.63 ± 0.87 and 0.85 ± 0.93 at 6, 12, 18, 24, 30 and 36 months after the operation, respectively. The postoperative MD slope was significantly more positive than the preoperative slope (estimated difference, 0.330 dB/year; SE, 0.116; p = 0.0084). Conclusions: These findings suggest that microhook ab interno trabeculotomy with phacoemulsification can reduce IOP and medication burden and improved visual acuity through 3 years. Although there is potential beneficial effect, further study will be needed to prove its effect on visual field progression.

  • Open Access

    Axonal Protection by Oral Nicotinamide Riboside Treatment with Upregulated AMPK Phosphorylation in a Rat Glaucomatous Degeneration Model

    by Ibuki Arizono, Naoki Fujita, Chihiro Tsukahara, Kana Sase, Reio Sekine, Tatsuya Jujo, Mizuki Otsubo, Naoto Tokuda, Yasushi Kitaoka

    Nicotinamide riboside (NR), a precursor of nicotinamide adenine dinucleotide (NAD+), has been studied to support human health against metabolic stress, cardiovascular disease, and neurodegenerative disease. In the present study, we investigated the effects of oral NR on axonal damage in a rat ocular hypertension model. Intraocular pressure (IOP) elevation was induced by laser irradiation and then the rats received oral NR of 1000 mg/kg/day daily. IOP elevation was seen 7, 14, and 21 days after laser irradiation compared with the controls. We confirmed that oral NR administration significantly increased NAD+ levels in the retina. After 3-week oral administration of NR, morphometric analysis of optic nerve cross-sections showed that the number of axons was protected compared with that in the untreated ocular hypertension group. Oral NR administration significantly prevented retinal ganglion cell (RGC) fiber loss in retinal flat mounts, as shown by neurofilament immunostaining. Immunoblotting samples from the optic nerves showed that oral NR administration augmented the phosphorylated adenosine monophosphate-activated protein kinase (p-AMPK) level in rats with and without ocular hypertension induction. Immunohistochemical analysis showed that some p-AMPK-immunopositive fibers were colocalized with neurofilament immunoreactivity in the control group, and oral NR administration enhanced p-AMPK immunopositivity. Our findings suggest that oral NR administration protects against glaucomatous RGC axonal degeneration with the possible upregulation of p-AMPK.


  • Open Access

    Axonal Protection by Tacrolimus with Inhibition of NFATc1 in TNF-Induced Optic Nerve Degeneration

    by Chihiro Tsukahara, Kana Sase, Naoki Fujita, Hitoshi Takagi, Yasushi Kitaoka

    Tacrolimus, a calcineurin (CaN) inhibitor, has been used for treatment of refractory allergic ocular disease, although its role in optic nerve degeneration remains to be elucidated. In this study, we investigated whether tacrolimus modulates tumor necrosis factor (TNF)-mediated axonal degeneration and whether it alters nuclear factor of activated T cells (NFATc), a downstream effector of CaN signaling. Immunoblot analysis showed no significant difference in CaNAα protein levels in optic nerve on day 3, 7, or 14 after TNF injection compared with PBS injection. However, a significant increase in NFATc1 protein level was observed in optic nerve 7 days after TNF injection. This increase was negated by simultaneous administration of tacrolimus. Administration of tacrolimus alone did not change the NFATc1 protein level in comparison to that observed after PBS injection. A significant increase in TNF protein level was observed in optic nerve 14 days after TNF injection and this increase was prevented by tacrolimus. Immunohistochemical analysis showed the immunoreactivity of NFATc1 to be increased in optic nerve after TNF injection. This increased immunoreactivity was colocalized with glial fibrillary acidic protein and was suppressed by tacrolimus. Treatment of tacrolimus significantly ameliorated the TNF-mediated axonal loss. These results suggest that tacrolimus is neuroprotective against axon loss in TNF-induced optic neuropathy and that the effect arises from suppression of the CaN/NFATc1 pathway.